🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

MajesTEC-5 - Arm A/A1: Teclistamab + Dara + Len --> ASCT --> Tec-Dara Arm B: Tec-Dara-V-R Toxicity: 60-70% CRS, G1-2; 35% G3+ infections (everybody getting some infections) Efficacy (amazing!) Everybody is MRD negative after just 3 cycles! Stem cell yields not affected To me,

#ASH2024 important update on the role of CTCs in myeloma #mmsm by Luca Bertamini Tom Cupedo and EMN! Clearly prognostic in patients treated with the new standard of care and complementary to cytogenetics. Ready for prime time assessment in trials and routine practice

#ASH24 just for context - in DETERMINATION published just a few years ago, MRD neg (10^-5) AFTER ASCT was ~54%. In MajesTEC-5, small n, but 100% MRD negativity BEFORE ASCT (after only 3 cycles)... + 1x-wkly V and #downwithdex! Amazing #MMsm data by Marc S. Raab Leo Rasche et al!

#ASH24 MajesTEC-4! Zamagni et al: Safety run-in for tec + len maintenance after ASCT. First time we're seeing bsAb maintenance data in #MMsm 👏 Bottom line: it works! But important to see: Tec as maintenance is same as tec in RRMM: CRS and infections can happen. Use IVIG!

A fantastic presentation by Doris Hansen comparing cilta-cel to ide-cel: A comprehensive weighting anaysis was performed to try to balance arms. What did they find? - Both in the ITT and as-treated cohorts, cilta-cel was associated with superior PFS and OS (not the early

Many patients with multiple myeloma experience persistent pain and use opioids to manage that pain even after they achieve remission, a survey suggests. Presented at #ASH24 by Karen Sweiss from University of Illinois Chicago. #mmsm cancertherapyadvisor.com/reports/multip…

More than half of patients newly diagnosed with lymphoma or myeloma experience significant anxiety or depression - we should expect therefore that the majority of these patients will need treatment. #mmsm ashpublications.org/bloodadvances/…

An imp emerging risk factor for CMV reactivation post-HSCT is pre-transplant CMV reactivation—even in the letermovir era. We must be cautious, screen, and treat these patients before transplant. #Tandem25 #Tandem2025

CMV antivirals, prophylaxis strategies, pre-emptive treatments, and resistance patterns: Key elements to monitor in high-risk HSCT recipients. #Tandem25 #CMV #HSCT

Moving to Maribavir: Fewer side effects (mainly taste disturbance) vs. myelosuppressive alternatives. However, it missed the non-inferiority cut-off in the AURORA trial for pre-emptive CMV Rx approval. #Tandem25 #CMV

#Myeloma Paper of the Day: A model for predicting day-100 stem cell transplant-related mortality in AL #amyloidosis using NT-proBNP/BNP, serum albumin, ECOG PS, and systolic BP w/ day-100 TRM of 0.46%, 3.2%, 5.8%, & 14.5% for 0, 1, 2, & ≥3 points: pubmed.ncbi.nlm.nih.gov/39994333/. #mmsm

“To write for impact means to keep it as simple as possible.” Good read and very insightful. nature.com/articles/s4158…

Long-term GMMG-RELAPSE in #MMsm, now officially in Blood Journal! Excellent 🇩🇪 trial that puts 🔩 in ⚰️ for 2nd ASCT unless no other options available. I'd missed these landmark analyses: no benefit even in pts who actually got 2nd ASCT or who had DOR > 4 yrs with first ASCT.

#ASCO25 : Abstract Titles Just Released meetings.asco.org/abstracts-pres…

Our work out now highlighting importance of ongoing assessment of opioid use especially during myeloma remission! ⁦Damiano Rondelli⁩ ⁦Craig Hofmeister⁩ ⁦⁦Ana María Ávila⁩ ⁦University of Illinois Cancer Center⁩ link.springer.com/article/10.100…

Balancing pain management vs. addiction risk in a HealthTree study - Karen Sweiss, PharmD at the HealthTree Chicago Roundtable #mmsm

The drug cyclophosphamide could revolutionise blood stem cell transplants, allowing transplants from “mismatched” donors, according to a new study. Read the latest #BSHNews story here: b-s-h.org.uk/about-us/news/…

A historic day for myeloma!! After 5 decades of research. European Commission / EMA approves Daratumumab as the first ever approved treatment for high risk smoldering myeloma based on the results of the AQUILA trial. Thanos Dimopoulos Plasma Cell Pete globenewswire.com/news-release/2…

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia ashpublications.org/blood/article/… 70 cases of B-cell #ALL with lineage switch after immunotherapy (anti-CD19) to AML or mixed phenotypic leukemia. Dismal outcome with